Authors:
Pan, LC
Carpino, PA
Lefker, BA
Ragan, JA
Toler, SM
Pettersen, JC
Nettleton, DO
Ng, O
Pirie, CM
Chidsey-Frink, K
Lu, BH
Nickerson, DF
Tess, DA
Mullins, MA
MacLean, DB
DaSilva-Jardine, PA
Thompson, DD
Citation: Lc. Pan et al., Preclinical pharmacology of CP-424,391, an orally active pyrazolidinone-piperidine growth hormone secretagogue (vol 14, pg 121, 2001), ENDOCRINE, 14(3), 2001, pp. 437-437
Authors:
Herrington, DM
Brosnihan, KB
Pusser, BE
Seely, EW
Ridker, PM
Rifai, N
MacLean, DB
Citation: Dm. Herrington et al., Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women, J CLIN END, 86(9), 2001, pp. 4216-4222
Authors:
Hennessey, JV
Chromiak, JA
DellaVentura, S
Reinert, SE
Puhl, J
Kiel, DP
Rosen, CJ
Vandenburgh, H
MacLean, DB
Citation: Jv. Hennessey et al., Growth hormone administration and exercise effects on muscle fiber type and diameter in moderately frail older people, J AM GER SO, 49(7), 2001, pp. 852-858
Authors:
Herrington, DM
Pusser, BE
Riley, WA
Thuren, TY
Brosnihan, KB
Brinton, EA
MacLean, DB
Citation: Dm. Herrington et al., Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthy postmenopausal women, ART THROM V, 20(6), 2000, pp. 1606-1612